Forward PE Ratio: 21.31
The forward PE ratio is 21.31 as of Thursday, July 9, 2026.
Forward PE Ratio (21.31) = Close Price ($133.59) / Consensus Forward EPS ($6.06)
A Forward PE Ratio Metrics
FORWARD PE RATIO
21.31
A Competitors' Forward PE Ratio
Agilent Technologies, Inc.
Market Cap
$37.73B
Forward PE Ratio
21.31
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Agilent Technologies, Inc. (A) | $37.73B | 21.31 |
| IQVIA Holdings Inc. (IQV)vs › | $34.88B | 15.90 |
| Medline Inc. (MDLN)vs › | $34.54B | 26.62 |
| Centene Corp. (CNC)vs › | $33.38B | 19.16 |
| Zoetis Inc. (ZTS)vs › | $31.48B | 10.91 |
| IDEXX Laboratories, Inc. (IDXX)vs › | $44.06B | 37.91 |
| Veeva Systems Inc. (VEEV)vs › | $30.82B | 23.70 |
| Moderna, Inc. (MRNA)vs › | $30.38B | N/A |
| ResMed Inc. (RMD)vs › | $30.24B | 18.53 |
| GE HealthCare Technologies Inc. (GEHC)vs › | $29.43B | 13.25 |
Trailing vs Forward
Trailing P/E
25.9
reported TTM EPS
Forward P/E
21.3
consensus next-FY EPS
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $6.06 implies +21.7% EPS growth vs the reported trailing $4.98.
Forward P/E by Fiscal Year
View All Analyst EstimatesAt today's $133.59 close, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-10-31 | $6.06 | $5.96 – $6.12 | 12 | 22.1x |
| 2027-10-31 | $6.60 | $6.47 – $6.70 | 12 | 20.2x |
| 2028-10-31 | $7.31 | $6.79 – $7.89 | 6 | 18.3x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
Forward PE Ratio Formula & Definition
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Forward PE Ratio FAQ
- What is the forward PE ratio for Agilent Technologies, Inc. (A)?
- The forward PE ratio for A stock is 21.31.
Related Metrics
About Agilent Technologies, Inc.
Agilent Technologies, Inc. delivers specialized, application-focused technologies and services to the global life sciences, diagnostics, and applied chemistry industries. Its Life Sciences and Applied Markets segment provides a comprehensive portfolio of analytical instrumentation. This includes liquid chromatography (LC) and gas chromatography (GC) systems, often integrated with mass spectrometry (MS) for advanced analysis (LC-MS, GC-MS). They also offer inductively coupled plasma mass spectrometry (ICP-MS), atomic absorption (AA), microwave plasma-atomic emission spectrometry (MP-AES), and inductively coupled plasma optical emission spectrometry (ICP-OES) instruments, alongside Raman spectroscopy for material characterization. Beyond spectroscopy, the segment supplies cell analysis solutions such as plate-based assays, flow cytometers, real-time cell analyzers, imaging systems, and microplate readers. Complementing these are various laboratory software, information management platforms, data analytics tools, automated and robotic lab systems, dissolution testing equipment, vacuum technology, and general measurement solutions. The Diagnostics and Genomics division offers cutting-edge tools for genetic and diagnostic research. These encompass arrays designed for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, and gene expression analysis. This segment also provides target enrichment solutions for next-generation sequencing, along with software for genetic data management and interpretation. Furthermore, it synthesizes custom oligonucleotides. Other significant offerings include immunohistochemistry (IHC), in situ hybridization (ISH), hematoxylin and eosin (H&E) staining, and specialized staining solutions. The division also supplies consumables and software essential for quality control analysis of nucleic acid samples, as well as reagents for turbidimetry and flow cytometry applications. A key area of development for this segment is liquid-based pharmacodiagnostics. Agilent CrossLab, the third segment, focuses on providing essential laboratory consumables and services. Its product range features GC and LC columns, products for sample preparation, custom chemical formulations, and various supplies for laboratory instruments. Complementary services include expert support for startup, ongoing operations, training, compliance, Software-as-a-Service (SaaS) offerings, asset management, and professional consultation. The company's products reach customers through a diverse sales network, including direct sales teams, distributors, resellers, manufacturer's representatives, and its e-commerce platforms. Agilent Technologies, Inc. was established in 1999 and maintains its corporate headquarters in Santa Clara, California.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Padraig McDonnell